CompoundsActive IngredientsBrivaracetam CAS 357336-20-0

SKU: WGP-357336-20-0




Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.

  • Description
  • Additional information


Brivaracetam CAS 357336-20-0 Product Information

Product Name:brivaracetam
Synonyms:(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;API-Anti Epilepsy;brivaracetam
CAS NO:357336-20-0
Molecular Weight:703.83
Molecular Formula:C33H41N3O10S2
Boiling Point:409.3±28.0 °C at 760 mmHg
Melting point:76.38°
Appearance:White to Off-White Solid
Applications:Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. It provides a new monotherapy treatment option for epilepsy patients 16 years of age and older who suffering partial-onset[focal] seizures, which can be initiated at a therapeutic dose at day one.
Solubility:DMSO (Slightly), Methanol (Slightly)

brivaracetam uses

Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.

brivaracetam loading dose/brivaracetam dose

1 month to 16 years:
Weight: Less than 11 kg: Initial dose: 0.75 to 1.5 mg/kg orally twice a day; Maintenance dose: 0.75 to 3 mg/kg orally twice a day
Weight: 11 kg to less than 20 kg: Initial dose: 0.5 to 1.25 mg/kg orally twice a day; Maintenance dose: 0.5 to 2.5 mg/kg orally twice a day
Weight: 20 kg to less than 50 kg: Initial dose: 0.5 to 1 mg/kg orally twice a day; Maintenance dose: 0.5 to 2 mg/kg orally twice a day
Weight: 50 kg or greater: Initial dose: 25 to 50 mg orally twice a day; Maintenance dose: 25 to 100 mg orally twice a day

16 years of age and older:
Initial dose: 50 mg orally 2 times a day
Maintenance dose: 25 mg to 100 mg orally twice a day

Customized packaging on demand

brivaracetam half life

Brivaracetam exhibits linear pharmacokinetics over a wide dose range, is rapidly and completely absorbed after oral administration, has an elimination half-life of seven to eight hours.

brivaracetam reviews

  • When initiating therapy, gradual dose escalation is not required; following initiation, dose should be adjusted based on clinical response and tolerability.
  • Tablets, oral solution and injection can be used interchangeably.

Our factory and lab

brivaracetam mechanism of action/how does brivaracetam work

Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam. but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.

brivaracetam vs levetiracetam/brivaracetam and leviracetam

Brivaracetam (BRV) is an AED in the racetam group which was discovered as an analog to the related racetam drug levetiracetam (LEV). Both drugs have a similar mechanism of action with a selective and high affinity for binding to synaptic vesicle protein 2A, but they may differ in their pharmacological profiles.

brivaracetam side effects

The most common adverse effects include sleepiness, dizziness, nausea and vomiting. More rarely, coordination problems and changes in behaviour (such as severe depression, aggression, hostility, impatience, rage, depression, suicide ideology, etc.) can occur.


Additional information

Melting Point


Boiling point 

409.3±28.0 °C(Predicted)




DMSO (Slightly), Methanol (Slightly)






There are no reviews yet.

Be the first to review “Brivaracetam CAS 357336-20-0”

error: Alert: Content is protected !!